Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by lscfaon Mar 19, 2024 1:48pm
76 Views
Post# 35941070

RE:Vote NO

RE:Vote NO

3% of asset sales to shareholders is robbery when Schutte only owns 27% of co.  Schutte can spend $100k-$200k to find a buyer and get 97% of proceeds. The 3% no. needs to be increased to at least 50%.


lscfa wrote: Shutte owns 27% of co. If he were to invest $2 million to get RP to commercialization he would own 55% of co. Does anyone really expect him to spend $2 million as a private co. or will he just shop the assets around until he finds a buyer?

 

 

Schutte

Total

Shutte %

Shs

17,401,616

65,001,560

26.8%

$2M @ .05/sh

40,000,000

40,000,000

100.0%

 

57,401,616

105,001,560

54.7%

 

 

 

 

 

Schutte

Total

Shutte %

Shs

17,401,616

65,001,560

26.8%

Wrts

6,744,776

11,384,559

59.2%

Options

1,155,000

4,075,000

28.3%

Convertible pref

250,000

1,089,125

23.0%

 

25,551,392

81,550,244

31.3%

 


 

<< Previous
Bullboard Posts
Next >>